Rafarma Pharmaceutical news update - Barrons

RAFA Stock  USD 0.06  0.01  8.96%   
About 62% of Rafarma Pharmaceuticals' investor base is looking to short. The analysis of overall sentiment of trading Rafarma Pharmaceuticals pink sheet suggests that many investors are alarmed at this time. The current market sentiment, together with Rafarma Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Rafarma Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
  
Rafarma Pharmaceutical news update Barrons

Read at news.google.com
Google News at Macroaxis
  

Rafarma Pharmaceuticals Fundamental Analysis

We analyze Rafarma Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rafarma Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rafarma Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Market Capitalization

Market Capitalization Comparative Analysis

Rafarma Pharmaceuticals is currently under evaluation in market capitalization category among its peers. Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.

Peers

Trending Equities

BBY  2.05   
0%
52.0%
INTC  0.69   
0%
17.0%
C  0.61   
0%
15.0%
UPS  0.17   
0%
4.0%
AAPL  0.07   
0%
1.0%
TGT  0.01   
0%
1.0%
WFC  0.00   
0%
0%
IBM  0.00   
0%
0%
S  0.00   
0%
0%
CVS  0.00   
0%
0%
MET  0.52   
13.0%
0%
HD  0.92   
23.0%
0%
AA  1.26   
32.0%
0%
AAL  1.86   
47.0%
0%
CVX  2.79   
71.0%
0%
T  3.89   
100.0%
0%

Complementary Tools for Rafarma Pink Sheet analysis

When running Rafarma Pharmaceuticals' price analysis, check to measure Rafarma Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rafarma Pharmaceuticals is operating at the current time. Most of Rafarma Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Rafarma Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rafarma Pharmaceuticals' price. Additionally, you may evaluate how the addition of Rafarma Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance